• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    IDEAYA Biosciences (IDYA) Stock Looks Priced At A Premium Despite R And D Promotion

    Simply Wall St·10/01/2026 02:17:11
    语音播报

    IDEAYA Biosciences has delivered strong multiyear gains, and with fresh leadership news in its research group, the focus turns to whether the current share price lines up with what its sales can reasonably support. For anyone tracking the stock after these moves, the big question is how much of that story is already reflected in the trading level.

    • Over the past 3 years, IDEAYA Biosciences has returned 50.8%, which raises the stakes on whether its revenue base and growth potential are enough to support that kind of share price progress.
    • The promotion of Dr. Michael White to President, Research and Development from late September 2026 may support expectations for IDEAYA's precision oncology pipeline, which could influence how investors think about future sales and the timing of potential cash inflows.
    • There is a second opinion on IDEAYA Biosciences worth weighing. See what analysts think IDEAYA Biosciences's shares could be worth.

    The stock's next move may depend on whether IDEAYA Biosciences' current market value is fully justified by its sales today and the revenue investors expect it to generate over time.

    If you want to test the same sales versus valuation question that IDEAYA Biosciences now faces across a wider set of companies, run the numbers through 32 high quality undervalued stocks.

    Does IDEAYA Biosciences Look Pricey on Sales?

    P/S is often a better fit for a biotech like IDEAYA Biosciences because reported earnings can swing around long before any approved products show up. On this measure, IDEAYA trades on a P/S of about 15.8x, compared with roughly 12.4x for the broader biotechs industry and around 16.6x across closer peers. This means the stock is priced toward the higher end of the range investors are currently paying for similar revenue profiles.

    Because the fair multiple model heavily penalises IDEAYA Biosciences for its current losses and risk profile, it flags the share as overvalued on a P/S basis rather than pointing to any precise target. The recent promotion of Dr. Michael White to President, Research and Development may help sentiment around the precision oncology pipeline, but the present valuation already assumes a lot from future sales relative to both the sector and that risk adjusted benchmark. Explore the numbers behind IDEAYA Biosciences's P/S valuation.

    NasdaqGS:IDYA P/S Ratio as at Oct 2026
    NasdaqGS:IDYA P/S Ratio as at Oct 2026

    The IDEAYA Biosciences Narrative: What Would Justify Today's Price?

    Simply Wall St Narratives pick up where that P/S puzzle for IDEAYA Biosciences leaves off. They spell out the specific growth, margin and earnings paths that would need to play out for the stock to be worth materially more or less than today’s price, and they turn a single model output into a concrete future you can monitor over time on Simply Wall St’s Community page.

    One of the top community narratives on IDEAYA Biosciences: 41% undervalued

    "A key focus for the company is successful execution on upcoming clinical and regulatory milestones for darovasertib and IDE849..."

    Discover why this Narrative puts IDEAYA Biosciences at 41% undervalued.

    One more IDEAYA Biosciences check that belongs beside the sales story

    Price, revenue and leadership moves only tell part of the IDEAYA Biosciences picture, because internal risk checks have flagged specific areas that investors may want to weigh before getting comfortable with the story. Take a closer look at 1 warning sign before settling on a valuation.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.